Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX)

Q: What does CUSIP 67080M103 represent in this 13F holders report?

CUSIP 67080M103 is the security identifier for NRIX - Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share used to aggregate holder disclosures.

Q: How many institutions held NRIX - Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share in Q3 2020?

64 institutional investors reported NRIX - Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share for Q3 2020. Use the holders table for investor-level position and value details.

CUSIP: 67080M103

Q3 2020 13F Holders as of 30 Sep 2020

Type / Class: Equity / Common Stock, par value $0.001 per share
Shares outstanding: 103,174,603
Total 13F shares: 31,854,383
Share change: +31,854,383
Total reported value: $1,111,189,598
Price per share: $34.91
Number of holders: 64
Value change: +$1,111,189,598
Number of buys: 64

Quarterly Holders Quick Answers

What is CUSIP 67080M103?
CUSIP 67080M103 identifies NRIX - Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q4 2020

Recent filing periods for CUSIP 67080M103:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of NRIX - Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

No top shareholder records were found across 13F, 13D/G, and Forms 3/4/5 for this issuer.

Institutional Holders of Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) as of Q3 2020

As of 30 Sep 2020, Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) was held by 64 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 31,854,383 shares. The largest 10 holders included Svennilson Peter, TRV GP III, LLC, WELLINGTON MANAGEMENT GROUP LLP, Redmile Group, LLC, Foresite Capital Management IV, LLC, BAKER BROS. ADVISORS LP, BOXER CAPITAL, LLC, Bain Capital Life Sciences Investors, LLC, EcoR1 Capital, LLC, and BlackRock Inc.. This page lists 64 institutional shareholders reporting positions in this security for the Q3 2020 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q3 2020 vs Q4 2025 Across Filers

Q4 2025 holders

182

Q3 2020 holders

Holder diff

-118

Investor	Q4 2025 Shares	Q3 2020 Shares	Share Diff	Share Chg %	Q4 2025 Value $	Q3 2020 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.